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sions of the EQ-5D were assigned level 1 (no problems) as RLS
was not considered to affect a patient’s basic care and mobility.
For dimension with more than one mapped level, a rounded
average was considered. Other dimensions were assumed to be
captured by the IRLS instrument. Signiﬁcant inverse correlation
was reported between the changes in utility scores and the
changes in IRLS sum scores (p < 0.001). The regression model
explains 56% of the variance in the changes in the utility
scores: change_in_utility_scores = 0.0049 - 0.0277*change_in_
IRLS_sum_scores. Similar results were found in the analyses for
the changes from baseline to month 3. CONCLUSIONS:
Changes in the EQ-5D derived utility scores can be reasonably
estimated from the changes in the IRLS sum scores among
patients with restless legs syndrome.
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OBJECTIVES: To evaluate the appropriateness of the Child
Health Questionnaire—Parent Form 50 (CHQ-PF50) in moni-
toring behavioral and emotional functioning in children with
epilepsy treated with antiepileptic drugs (AEDs), by comparing
and correlating it with the Child Behavior Checklist (CBCL).
METHODS: Clinical data from a double-blind placebo (PBO)
controlled study of adjunctive therapy of levetiracetam (20–
60 mg/kg/day) in children (4–16y) with partial onset seizures
(POS), which included the CBCL and the CHQ-PF50 to assess
behavioral and emotional functioning, were used. Pearson cor-
relation coefﬁcients between scores of the two instruments mea-
suring similar concepts were calculated, and the two instruments
were compared for item content, acceptability, reliability, validity
and responsiveness to various factors. RESULTS: 78 patients had
CHQ-PF50 and CBCL data at baseline and evaluation (12
weeks). Both questionnaires showed good acceptability in terms
of return rates (81.6% at the lowest) and missing data (average/
patient < 1%). All subscales except CHQ-PF50 General Health
showed good reliability in terms of Crohnbach’s a (r > 0.700).
All scores of the CHQ-PF50 measuring behavioral or emotional
functioning (Behavior, Mental Health, Role/Social Limitations-
Emotional/Behavioral and the Psychosocial Summary Score)
showed large correlations with CBCL scores measuring similar
concepts (-0.821 < -0.433) at baseline but smaller correlations
for change from baseline (-0.470 < -0.030). CHQ-PF50
behavior-related scores seemed more responsive to the occur-
rence of behavioral adverse events than corresponding CBCL
scores, although both showed limited sensitivity (small Standard-
ized Response Means). The CBCL Externalizing score, however,
appeared to be more sensitive when comparing treatment groups
than the corresponding CHQ-PF50 Behavior score (p = 0.011 vs.
p = 0.871 from ANCOVA). CONCLUSIONS: The CHQ-PF50
scores assessing behavioral and emotional functioning have
shown good reliability, validity, and high consistency with the
corresponding CBCL scores. However, the behavior score of the
CHQ-PF50 appeared to be less sensitive in showing between-
treatment group differences than the more speciﬁc and compre-
hensive Externalizing score of the CBCL.
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OBJECTIVES: To evaluate patient and physician satisfaction
with the use of a Brief Dementia Screening test for Parkinson’s
disease (PD-BDST) in a clinical practice setting. METHODS:
An observational, cross-sectional and multicenter study was
conducted, including 471 PD patients. The PD-BDST and Mini-
Mental State Examination (MMSE) were administered to
patients. A patient satisfaction questionnaire rated with a visual
scale from 0 to 10 was used to assess patient satisfaction. Phy-
sician satisfaction (n = 52) was measured using a satisfaction
questionnaire rated with a Likert scale from 0 to 5. RESULTS:
The mean PD-BDST score (SD) was 18.5  6.3, and 36.3%
of patients presented scores compatible with dementia (PD-
BDST score 15 points). There was a high correlation between
the score of the Mini-Mental test (29.05  5.4) and the
PD-BDST scores (r = 0.73, p < 0.001). Mean satisfaction scores
for patients and physician were 27.6  7.4 and 3.60  0.58,
respectively. A total of 37.7% of patients reported not having
any trouble completing the test, and 22.6% expressed difﬁcul-
ties in only one part of the test. The proportion of satisﬁed
patients was 77.3%. Patients with the least risk of poor satis-
faction were those with a PD-BDST higher score (OR = 0.9) and
those reporting less difﬁculties completing the test (OR = 0.8).
More than half of physicians presented a score higher than
3.73. The mean scores for PD-BDST applicability, handling and
reliability of physicians were 3.5  0.7, 3.7  0.6 y 3.1  0.5.
CONCLUSIONS: Previous studies have shown the PD-BDST to
be a speciﬁc test to diagnose PD-related dementia able to dis-
tinguish between healthy controls, non-demented PD and
demented PD. In the present study, PD patients found the
PD-BDST satisfactory. Participating investigators considered the
test to be valid, quick and simple to administer in a clinical
practice setting.
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OBJECTIVES: Insomnia is prevalent in many populations, both
as a primary disorder and as a symptom secondary to a medi-
cation or underlying condition. The objective of this study was
to assess patient satisfaction with a variety of insomnia medi-
cations used in a community-based population in the U.S.
METHODS: Patients are recruited from multiple sources
including physician, pharmacy and online referrals and asked to
report ongoing medications on the project website (www.
iGuard.org). A random sample of patients are contacted to
complete the Treatment Satisfaction Questionnaire for Medica-
tion Version 1.4 (TSQM), a 14-item reliable and valid instru-
ment to assess patients’ satisfaction with medication, providing
scores on four scales—effectiveness, side effects, convenience
and global satisfaction. TSQM scores range from 0 to 100, with
higher scores indicating higher satisfaction on the domain.
Analyses were conducted to explore differences in patient sat-
isfaction across insomnia medications. RESULTS: A total of
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